Business Wire·Dec 10, 2025, 4:15 PM ET

Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America

Cerus Corporation (NASDAQ: CERS) entered a group purchasing agreement with Blood Centers of America (BCA), the largest U.S. blood supply cooperative.
The agreement covers Cerus' entire INTERCEPT product line & aims to expand access to pathogen reduction technology for platelets, plasma, & INTERCEPT Fibrinogen Complex (IFC).
BCA member blood centers produce approximately half of the U.S. platelet & cryoprecipitate supply & represent over 60 independent community blood centers.
Under the deal, ongoing IFC production at BCA member centers will utilize a resource-sharing model to facilitate easier access & distribution to blood centers & hospitals.
Cerus & BCA will collaborate on training & education initiatives to increase awareness & adoption of pathogen reduction technologies.
Cerus' INTERCEPT Blood System holds CE mark & FDA approval for platelets & plasma, with its cryoprecipitation system approved in the U.S. for producing pathogen-reduced cryoprecipitated fibrinogen complex.